About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 65741, 10 pages
http://dx.doi.org/10.1155/JBB/2006/65741
Review Article

HIV Neurotoxicity: Potential Therapeutic Interventions

Department of Pharmacology and Physiology and Department of Forensic Sciences, Center for Health Sciences, Oklahoma State University, Tulsa, OK 74107-1898, USA

Received 1 December 2005; Revised 21 February 2006; Accepted 27 February 2006

Copyright © 2006 David R. Wallace. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B A Bennett, D E Rusyniak, and C K Hollingsworth, “HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures,” Brain Research, vol. 705, no. 1-2, pp. 168–176, 1995. View at Publisher · View at Google Scholar
  2. A Nath, K Psooy, C Martin, et al., “Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic,” Journal of Virology, vol. 70, no. 3, pp. 1475–1480, 1996.
  3. J Cheng, A Nath, B Knudsen, et al., “Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein,” Neuroscience, vol. 82, no. 1, pp. 97–106, 1998. View at Publisher · View at Google Scholar
  4. M Y Aksenov, U Hasselrot, A K Bansal, et al., “Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum,” Neuroscience Letters, vol. 305, no. 1, pp. 5–8, 2001. View at Publisher · View at Google Scholar
  5. A K Bansal, C F Mactutus, A Nath, et al., “Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum,” Brain Research, vol. 879, no. 1-2, pp. 42–49, 2000. View at Publisher · View at Google Scholar
  6. M Y Aksenov, U Hasselrot, G Wu, et al., “Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum,” Brain Research, vol. 987, no. 1, pp. 1–9, 2003. View at Publisher · View at Google Scholar
  7. II Kruman, A Nath, and M P Mattson, “HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress,” Experimental Neurology, vol. 154, no. 2, pp. 276–288, 1998. View at Publisher · View at Google Scholar
  8. E S Gavriil, R Cooney, and B S Weeks, “Tat mediates apoptosis in vivo in the rat central nervous system,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 252–256, 2000. View at Publisher · View at Google Scholar
  9. N J Haughey, C P Holden, A Nath, et al., “Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat,” Journal of Neurochemistry, vol. 73, no. 4, pp. 1363–1374, 1999. View at Publisher · View at Google Scholar
  10. D R New, S B Maggirwar, L G Epstein, et al., “HIV-1 Tat induces neuronal death via tumor necrosis factor-α and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism,” The Journal of Biological Chemistry, vol. 273, no. 28, pp. 17852–17858, 1998. View at Publisher · View at Google Scholar
  11. A Nath, N J Haughey, M Jones, et al., “Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine,” Annals of Neurology, vol. 47, no. 2, pp. 186–194, 2000. View at Publisher · View at Google Scholar
  12. E Polazzi, G Levi, and L Minghetti, “Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures,” Journal of Neuropathology and Experimental Neurology, vol. 58, no. 8, pp. 825–831, 1999.
  13. G Bagetta, M T Corasaniti, A M Paoletti, et al., “HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2),” Biochemical and Biophysical Research Communications, vol. 244, no. 3, pp. 819–824, 1998. View at Publisher · View at Google Scholar
  14. M C Yeung, F Geertsma, J Liu, et al., “Inhibition of HIV-1 gp120-induced apoptosis in neuroblastoma SK-N-SH cells by an antisense oligodeoxynucleotide against p53,” AIDS, vol. 12, no. 4, pp. 349–354, 1998. View at Publisher · View at Google Scholar
  15. J Raber, S M Toggas, S Lee, et al., “Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase,” Virology, vol. 226, no. 2, pp. 362–373, 1996. View at Publisher · View at Google Scholar
  16. N Sacktor, N Haughey, R Cutler, et al., “Novel markers of oxidative stress in actively progressive HIV dementia,” Journal of Neuroimmunology, vol. 157, no. 1-2, pp. 176–184, 2004. View at Publisher · View at Google Scholar
  17. A Perl and K Banki, “Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease,” Antioxidants & Redox Signaling, vol. 2, no. 3, pp. 551–573, 2000.
  18. N J Haughey and M P Mattson, “Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, no. suppl 2, pp. S55–S61, 2002.
  19. A Nath, “Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia,” The Journal of Infectious Diseases, vol. 186, no. suppl 2, pp. S193–S198, 2002. View at Publisher · View at Google Scholar
  20. A Minagar, P Shapshak, R Fujimura, et al., “The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis,” Journal of the Neurological Sciences, vol. 202, no. 1-2, pp. 13–23, 2002. View at Publisher · View at Google Scholar
  21. G A Garden, W Guo, S Jayadev, et al., “HIV associated neurodegeneration requires p53 in neurons and microglia,” The FASEB Journal, vol. 18, no. 10, pp. 1141–1143, 2004.
  22. A J Bruce-Keller, A Chauhan, F O Dimayuga, et al., “Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain,” The Journal of Neuroscience, vol. 23, no. 23, pp. 8417–8422, 2003.
  23. A Chauhan, J Turchan, C Pocernich, et al., “Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 13512–13519, 2003. View at Publisher · View at Google Scholar
  24. B Y Zhou, Y Liu, B Kim, et al., “Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes,” Molecular and Cellular Neuroscience, vol. 27, no. 3, pp. 296–305, 2004.
  25. V K Khurdayan, S Buch, N El-Hage, et al., “Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro,” European Journal of Neuroscience, vol. 19, no. 12, pp. 3171–3182, 2004. View at Publisher · View at Google Scholar
  26. S D Mahajan, R Aalinkeel, J L Reynolds, et al., “Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells,” Current HIV Research , vol. 3, no. 3, pp. 277–288, 2005. View at Publisher · View at Google Scholar
  27. M V Catani, M T Corasaniti, M Ranalli, et al., “The Tat antagonist neomycin B hexa-arginine conjugate inhibits gp-120-induced death of human neuroblastoma cells,” Journal of Neurochemistry, vol. 84, no. 6, pp. 1237–1245, 2003. View at Publisher · View at Google Scholar
  28. V Pandey and S R Bolsover, “Immediate and neurotoxic effects of HIV protein gp120 act through CXCR4 receptor,” Biochemical and Biophysical Research Communications, vol. 274, no. 1, pp. 212–215, 2000. View at Publisher · View at Google Scholar
  29. M Kaul and S A Lipton, “Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 8212–8216, 1999. View at Publisher · View at Google Scholar
  30. J Zheng, M R Thylin, A Ghorpade, et al., “Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia,” Journal of Neuroimmunology, vol. 98, no. 2, pp. 185–200, 1999. View at Publisher · View at Google Scholar
  31. V J Sanders, I P Everall, R W Johnson, et al., “Fibroblast growth factor modulates co-receptor CXCR4 expression by neural cells. HNRC {Group},” Journal of Neuroscience Research, vol. 59, no. 5, pp. 671–679, 2000. View at Publisher · View at Google Scholar
  32. M V Catani, M T Corasaniti, M Navarra, et al., “Gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors,” Journal of Neurochemistry, vol. 74, no. 6, pp. 2373–2379, 2000. View at Publisher · View at Google Scholar
  33. P Bezzi, M Domercq, L Brambilla, et al., “CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity,” Nature Neuroscience, vol. 4, no. 7, pp. 702–710, 2001. View at Publisher · View at Google Scholar
  34. F Noorbakhsh, N Vergnolle, J C McArthur, et al., “Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection,” Journal of Immunology, vol. 174, no. 11, pp. 7320–7329, 2005.
  35. M Z Khan, S Shimizu, J P Patel, et al., “Regulation of neuronal P53 activity by CXCR 4,” Molecular and Cellular Neurosciences, vol. 30, no. 1, pp. 58–66, 2005. View at Publisher · View at Google Scholar
  36. A Bachis and I Mocchetti, “The chemokine receptor CXCR4 and not the N-methyl-D-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells,” Journal of Neuroscience Research, vol. 75, no. 1, pp. 75–82, 2004. View at Publisher · View at Google Scholar
  37. Z G Jiang, C Piggee, M P Heyes, et al., “Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages,” Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 97–107, 2001. View at Publisher · View at Google Scholar
  38. S M Toggas, E Masliah, and L Mucke, “Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine,” Brain Research, vol. 706, no. 2, pp. 303–307, 1996. View at Publisher · View at Google Scholar
  39. P Wu, P Price, B Du, et al., “Direct cytotoxicity of HIV-1 envelope protein gp120 on human NT neurons,” Neuroreport, vol. 7, no. 5, pp. 1045–1049, 1996.
  40. S Vesce, P Bezzi, D Rossi, et al., “HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid,” FEBS Letters, vol. 411, no. 1, pp. 107–109, 1997. View at Publisher · View at Google Scholar
  41. C P Holden, N J Haughey, A Nath, et al., “Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes,” Neuroscience, vol. 91, no. 4, pp. 1369–1378, 1999. View at Publisher · View at Google Scholar
  42. A Perez, A W Probert, K K Wang, et al., “Evaluation of HIV-1 Tat induced neurotoxicity in rat cortical cell culture,” Journal of Neurovirology, vol. 7, no. 1, pp. 1–10, 2001. View at Publisher · View at Google Scholar
  43. D G Smith, G J Guillemin, L Pemberton, et al., “Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat,” Journal of Neurovirology, vol. 7, no. 1, pp. 56–60, 2001. View at Publisher · View at Google Scholar
  44. K J Swartz, M J During, A Freese, et al., “Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors,” The Journal of Neuroscience, vol. 10, no. 9, pp. 2965–2973, 1990.
  45. G Gras, F Chretien, A V Vallat-Decouvelaere, et al., “Regulated expression of sodium-dependent glutamate transporters and synthetase: a neuroprotective role for activated microglia and macrophages in HIV infection?” Brain Pathology, vol. 13, no. 2, pp. 211–222, 2003.
  46. T Chandra, W Maier, H G Konig, et al., “Molecular interactions of the type 1 human immunodeficiency virus transregulatory protein Tat with N-methyl-d-aspartate receptor subunits,” Neuroscience, vol. 134, no. 1, pp. 145–153, 2005. View at Publisher · View at Google Scholar
  47. K M Boje, “Nitric oxide neurotoxicity in neurodegenerative diseases,” Frontiers in Bioscience, vol. 9, pp. 763–776, 2004.
  48. G Bagetta, S Piccirilli, C Del Duca, et al., “Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat,” Neuroscience Letters, vol. 356, no. 3, pp. 183–186, 2004. View at Publisher · View at Google Scholar
  49. A Scorziello, T Florio, A Bajetto, et al., “TGF-beta1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death,” Journal of Neuroscience Research, vol. 49, no. 5, pp. 600–607, 1997. View at Publisher · View at Google Scholar
  50. B Shi, J Raina, A Lorenzo, et al., “Neuronal apoptosis induced by HIV-1 Tat protein and TNF-alpha: potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia,” Journal of Neurovirology, vol. 4, no. 3, pp. 281–290, 1998.
  51. W Chen, J Sulcove, I Frank, et al., “Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway,” Journal of Virology, vol. 76, no. 18, pp. 9407–9419, 2002. View at Publisher · View at Google Scholar
  52. L A Ryan, H Peng, D A Erichsen, et al., “TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia,” Journal of Neuroimmunology, vol. 148, no. 1-2, pp. 127–139, 2004. View at Publisher · View at Google Scholar
  53. M T Corasaniti, C Bellizzi, R Russo, et al., “Caspase-1 inhibitors abolish deleterious enhancement of COX-2 expression induced by HIV-1 gp120 in human neuroblastoma cells,” Toxicology Letters, vol. 139, no. 2-3, pp. 213–219, 2003. View at Publisher · View at Google Scholar
  54. E Acquas, A Bachis, R L Nosheny, et al., “Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases,” Neurotoxicity Research, vol. 5, no. 8, pp. 605–615, 2004.
  55. I N Singh, R J Goody, C Dean, et al., “Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: differential involvement of caspase-3 and endonuclease G,” Journal of Neurovirology, vol. 10, no. 3, pp. 141–151, 2004. View at Publisher · View at Google Scholar
  56. R A Clark and R Bessinger, “Clinical manifestations and predictors of survival in older women infected with HIV,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 15, no. 5, pp. 341–345, 1997.
  57. L S Schneider, “Estrogen and dementia: insights from the woman's health initiative memory study,” The Journal of the American Medical Association, vol. 291, no. 24, pp. 3005–3007, 2004. View at Publisher · View at Google Scholar
  58. P S Green and J W Simpkins, “Neuroprotective effects of estrogens: potential mechanisms of action,” International Journal of Developmental Neuroscience, vol. 18, no. 4-5, pp. 347–358, 2000. View at Publisher · View at Google Scholar
  59. L M Garcia-Segura, I Azcoitia, and L L DonCarlos, “Neuroprotection by estradiol,” Progress in Neurobiology, vol. 63, no. 1, pp. 29–60, 2001. View at Publisher · View at Google Scholar
  60. P S Green, K Gordon, and J W Simpkins, “Phenolic A ring requirement for the neuroprotective effects of steroids,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 63, no. 4–6, pp. 229–235, 1997. View at Publisher · View at Google Scholar
  61. S M Smith, G B Baskin, and P A Marx, “Estrogen protects against vaginal transmission of simian immunodeficiency virus,” The Journal of Infectious Diseases, vol. 182, no. 3, pp. 708–715, 2000. View at Publisher · View at Google Scholar
  62. J Turchan, C Anderson, K F Hauser, et al., “Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine,” BMC Neuroscience, vol. 2, p. 3, 2001. View at Publisher · View at Google Scholar
  63. Y W Lee, S Y Eum, A Nath, et al., “Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells,” Cardiovascular Research, vol. 63, no. 1, pp. 139–148, 2004. View at Publisher · View at Google Scholar
  64. V Hawkins, Q Shen, and C C Chiueh, “Kynostatin and 17beta-estradio prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease,” Journal of Biomedical Science, vol. 6, no. 6, pp. 433–438, 1999.
  65. S L Kendall, C F Anderson, A Nath, et al., “Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism,” BMC Neuroscience, vol. 6, no. 1, p. 40, 2005. View at Publisher · View at Google Scholar
  66. M T Corasaniti, D Amantea, R Russo, et al., “17beta-estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat,” Neurotoxicology, vol. 26, no. 5, pp. 893–903, 2005. View at Publisher · View at Google Scholar
  67. S M Brooke and R M Sapolsky, “The effects of steroid hormones in HIV-related neurotoxicity: a mini review,” Biological Psychiatry, vol. 48, no. 9, pp. 881–893, 2000. View at Publisher · View at Google Scholar
  68. S Brooke, R Chan, S Howard, et al., “Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 17, pp. 9457–9462, 1997. View at Publisher · View at Google Scholar
  69. A M Iyer, S M Brooke, and R M Sapolsky, “Glucocorticoids interact with gp120 in causing neurotoxicity in striatal cultures,” Brain Research, vol. 808, no. 2, pp. 305–309, 1998. View at Publisher · View at Google Scholar
  70. A Yusim, L Franklin, S Brooke, et al., “Glucocorticoids exacerbate the deleterious effects of gp120 in hippocampal and cortical explants,” Journal of Neurochemistry, vol. 74, no. 3, pp. 1000–1007, 2000. View at Publisher · View at Google Scholar
  71. S A Howard, A Y Nakayama, S M Brooke, et al., “Glucocorticoid modulation of gp120-induced effects on calcium-dependent degenerative events in primary hippocampal and cortical cultures,” Experimental Neurology, vol. 158, no. 1, pp. 164–170, 1999. View at Publisher · View at Google Scholar
  72. J R Berger and A Nath, “HIV dementia and the basal ganglia,” Intervirology, vol. 40, no. 2-3, pp. 122–131, 1997.
  73. L Hudson, J Liu, A Nath, et al., “Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues,” Journal of Neurovirology, vol. 6, no. 2, pp. 145–155, 2000.
  74. II Kruman, A Nath, W F Maragos, et al., “Evidence that Par-4 participates in the pathogenesis of HIV encephalitis,” The American Journal of Pathology, vol. 155, no. 1, pp. 39–46, 1999.
  75. T O Price, N Ercal, R Nakaoke, et al., “HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells,” Brain Research, vol. 1045, no. 1-2, pp. 57–63, 2005.
  76. A Nath, C Anderson, M Jones, et al., “Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia,” Journal of Psychopharmacology, vol. 14, no. 3, pp. 222–227, 2000.
  77. J A Gurwell, A Nath, Q Sun, et al., “Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro,” Neuroscience, vol. 102, no. 3, pp. 555–563, 2001. View at Publisher · View at Google Scholar
  78. C Power, J C McArthur, A Nath, et al., “Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients,” Journal of Virology, vol. 72, no. 11, pp. 9045–9053, 1998.
  79. G J Wang, L Chang, N D Volkow, et al., “Decreased brain dopaminergic transporters in HIV-associated dementia patients,” Brain, vol. 127, no. 11, pp. 2452–2458, 2004. View at Publisher · View at Google Scholar
  80. W E Muller, G Pergande, H Ushijima, et al., “Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention,” Progress in Molecular and Subcellular Biology, vol. 16, pp. 44–57, 1996.
  81. K K Jain, “Evaluation of memantine for neuroprotection in dementia,” Expert opinion on Investigational Drugs, vol. 9, no. 6, pp. 1397–1406, 2000. View at Publisher · View at Google Scholar
  82. C C Chao, S Hu, G Gekker, et al., “U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression,” Neuropharmacology, vol. 39, no. 1, pp. 150–160, 2000. View at Publisher · View at Google Scholar
  83. D R Wallace, S L Dodson, A Nath, et al., “Delta opioid agonists attenuate TAT1-72-induced oxidative stress in SK-N-SH cells,” NeuroToxicology, vol. 27, no. 1, pp. 101–107, 2006. View at Publisher · View at Google Scholar
  84. D R Wallace, S Dodson, A Nath, et al., “Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function,” Synapse, vol. 59, no. 1, pp. 51–60, 2006. View at Publisher · View at Google Scholar
  85. S A Howard, S M Brooke, and R M Sapolsky, “Mechanisms of estrogenic protection against gp120-induced neurotoxicity,” Experimental Neurology, vol. 168, no. 2, pp. 385–391, 2001. View at Publisher · View at Google Scholar
  86. I Zemlyak, S M Brooke, and R M Sapolsky, “Protection against gp120-induced neurotoxicity by an array of estrogenic steroids,” Brain Research, vol. 958, no. 2, pp. 272–276, 2002. View at Publisher · View at Google Scholar
  87. L Pulliam, I Irwin, L Kusdra, et al., “CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation,” Brain Research, vol. 893, no. 1-2, pp. 95–103, 2001. View at Publisher · View at Google Scholar
  88. D B Clifford, J C McArthur, G Schifitto, et al., “A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment,” Neurology, vol. 59, no. 10, pp. 1568–1573, 2002.
  89. J B Johnston, K Zhang, C Silva, et al., “HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors,” Annals of Neurology, vol. 49, no. 2, pp. 230–241, 2001. View at Publisher · View at Google Scholar
  90. I P Everall, C Bell, M Mallory, et al., “Lithium ameliorates HIV-gp120-mediated neurotoxicity,” Molecular and Cellular Neurosciences, vol. 21, no. 3, pp. 493–501, 2002. View at Publisher · View at Google Scholar
  91. J Turchan, C B Pocernich, C Gairola, et al., “Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants,” Neurology, vol. 60, no. 2, pp. 307–314, 2003.
  92. C B Pocernich, R Sultana, E Hone, et al., “Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes,” Journal of Neuroscience Research, vol. 77, no. 4, pp. 532–539, 2004. View at Publisher · View at Google Scholar
  93. C B Pocernich, R Sultana, A H Mohmmad, A Nath, and D A Butterfield, “HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations,” Brain Research. Brain Research Reviews, vol. 50, no. 1, pp. 14–26, 2005. View at Publisher · View at Google Scholar
  94. R L Nosheny, I Mocchetti, and A Bachis, “Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration,” Neurotox Research, vol. 8, no. 1-2, pp. 187–198, 2005.